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E-mail address: chris.drakeley@lshtm.ac.uk (C.J. DrMalaria-infected individuals can develop antibodies which reduce the infectiousness of Plasmodium
gametocytes to biting Anopheles mosquitoes. When ingested in a bloodmeal together with gametocytes,
these antibodies reduce or prevent subsequent parasite maturation in the insect host. This transmission-
blocking immunity is usually measured in human sera by testing its effect on the infectivity of
gametocytes grown in vitro. Here we evaluate evidence of transmission-blocking immunity in eight
studies conducted in three African countries. Plasmodium falciparum gametocytes isolated from each indi-
vidual were fed to mosquitoes in both autologous plasma collected with the parasites, and permissive
serum from non-exposed donors. Evidence of transmission reducing effects of autologous plasma was
found in all countries. Experiments involving 116 Gambian children (aged 0.5–15 years) were combined
to determine which factors were associated with transmission reducing immune responses. The chances
of infecting at least one mosquito and the average proportion of infected mosquitoes were negatively
associated with recent exposure to gametocytes and sampling late in the season. These results suggest
that effective malaria transmission-reducing antibodies do not commonly circulate in African children,
and that recent gametocyte carriage is required to initiate and/or boost such responses.
 2010 Australian Society for Parasitology Inc. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Recent successes in malaria control (Barnes et al., 2005, 2009;
Bhattarai et al., 2007; Ceesay et al., 2008; Kleinschmidt et al.,
2009) have resulted in optimism about the possibility of eliminat-
ing malaria in many areas where the disease is currently endemic
(Guerra et al., 2008). Transmission reducing interventions are now
acknowledged as key components of malaria control and elimina-
tion efforts (Greenwood, 2008; Greenwood et al., 2008; White,
2008). The transmission of malaria depends on the presence of
infectious sexual stage malaria parasites, gametocytes, in the
human peripheral blood. These gametocytes do not cause clinical
disease but once ingested by mosquitoes taking a blood meal,
can develop into ookinetes, oocysts and ultimately sporozoites,
thereby rendering the mosquito infectious to human beings. TheInc. Published by Elsevier Ltd.
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Opinfectiousness of gametocytes is inﬂuenced by their concentration
(Jeffery and Eyles, 1955; Tchuinkam et al., 1993; Schneider et al.,
2007), degree of maturity (Targett et al., 2001; Hallett et al.,
2006) and by mosquito (Whitten et al., 2006) and human immune
responses (Bousema et al., 2006a). The development of a human
immune response to gametocytes is not surprising given that the
vast majority of gametocytes are not taken up by mosquitoes but
are cleared by the host immune system. There is indirect evidence
that human immune responses may actively clear circulating
gametocytes after recognising antigens on the gametocyte-
infected erythrocyte (Baird et al., 1991; Taylor and Read, 1997;
Saeed et al., 2008). A distinct human immune response may also
reduce the infectiousness of gametocytes. Naturally occurring
transmission reducing activity (TRA) has been associated with
antibodies against antigens that are internally expressed in game-
tocytes but appear on the surface of gametes after gametocytes
have been ingested by mosquitoes, notably Pfs48/45 and Pfs230
(Carter et al., 1990; Roeffen et al., 1995; Bousema et al., 2006a).
TRA forms the basis for the development of transmission blocking
vaccines (Carter et al., 2000; Pradel, 2007; Saul, 2008) that could
play a key role in malaria elimination efforts (Sauerwein, 2007;
Targett and Greenwood, 2008; Greenwood and Targett, 2009) inen access under CC BY license.
Table 1
Summary membrane-feeding experiments on microscopically conﬁrmed gametocyte carriers with paired Autologous Plasma (AP) and Control Serum (CS) observations. Only
gametocyte carriers who had a minimum of 10 mosquitoes dissected in both AP and CS feeds were included in the analyses.
Country Year Timing of membrane feed experiments Median gametocyte
density (IQR)
Number of combined
AP-CS feeds (total
mosquitoes CS;AP)
% successful
feeds (n/N)a
Farafenni, The Gambia 1998 (Targett et al., 2001) Four (n = 45) or 7 days (n = 10)
after treatment with CQ, SP,
SP + AS1 or SP + AS3
120 (48–376) 55 (1439;1272) 56.4 (31/55)
Farafenni, The Gambia 1999 (Targett et al., 2001) Seven days after treatment with SP or SP + AS3 20 (10–220) 33(701;715) 100.0 (33/33)
Farafenni, The Gambia 2000 (Drakeley et al., 2004) Seven days after treatment with CQ or CQ + AS3 50 (10–245) 38 (652;622) 73.7 (28/38)
Farafenni, The Gambia 2001 (Hallett et al., 2006) Seven (n = 27), 10 (n = 6) or 14 (n = 8) days
after treatment with CQ, SP or CQ + SP
100 (35–615) 41(782;750) 48.8 (20/41)
Farafenni, The Gambia 2002 (Sutherland et al., 2005) Seven days after treatment with CQ + SP or AL 53 (20–160) 19(368;373) 21.1 (4/19)
Farafenni, The Gambia 1998–2002 After treatment with anti-malarials 65(20–320) 186 (3942; 3732) 62.4 (116/186)
Mbita, Kenya 2009 After treatment with AL or DP 200 (120–440) 12 (360;360) 91.6 (11/12)
Mengang, Cameroon 1 1997 (Bonnet et al., 2000;
Gouagna et al., 2004)
Prior to treatment 192 (80–608) 19 (519;540) 100 (19/19)
Yaoundé, Cameroon 2 1995 (Mulder et al., 1999) Prior to treatment 296 (88–536) 55 (1465;1086) 100 (55/55)
Bold lines indicate the summary ﬁgures per country.
IQR, interquartile range (25th–75th percentile); CQ, chloroquine; SP, sulphadoxine-pyrimethamine; AS1, one dose of artesunate given together with SP; AS3, three doses of
artesunate; AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine.
a Deﬁned as at least one infected mosquito in feeding experiment using AP and CS.
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mosquitoes can be infected.
Two types of assays are commonly used to detect TRA: the stan-
dard membrane feeding assay (SMFA) and the direct membrane
feeding assay (DMFA) (Bousema et al., 2006a). In the SMFA, cul-
tured gametocytes are fed to Anophelesmosquitoes in the presence
of an (endemic) test serum or plasma or non-malaria control serum
(Ponnudurai et al., 1989); in the DMFA, which can be conducted in
the ﬁeld, blood samples from naturally infected gametocyte carri-
ers are fed to mosquitoes in the presence of autologous plasma
(AP) or control serum (CS), after a washing step (Tchuinkam
et al., 1993). Advantages of the DMFA are that it uses parasite
strains that are naturally circulating in the study population, game-
tocyte densities that are representative of the natural situation and
locally caught and reared mosquitoes. The DMFA may therefore
resemble the natural situation better than the SMFA. However,
due to the labour intensiveness of the assay, depending on the dis-
section of typically 20–60 mosquitoes per experiment, studies
using DMFA are often too small to reliably conﬁrm the existence
of TRA in endemic populations, let alone to explore factors associ-
ated with TRA. Consequently, several fundamental questions about
the nature of TRA remain. TRA is thought to be rapidly induced
(Bousema et al., 2006b) but short-lived (Bousema et al., 2006a,
2007; Drakeley et al., 2006b) but both of these assertions are yet
to be conﬁrmed in ﬁeld studies. To investigate the induction, dura-
tion and efﬁcacy of anti-gamete antibodies in natural infections,
we determined the presence of TRA and associated factors in com-
bined data from eight membrane-feeding studies conducted in The
Gambia, Kenya and Cameroon.2. Materials and methods
2.1. Field studies
Data from eight trials with naturally infected individuals from
The Gambia, Kenya and Cameroon were included in the current
study (Table 1). With the exception of a subset of the experiments
from Cameroon, these data were not previously analysed to deter-
mine TRA. Experiments from The Gambia and Kenya involved feeds
on blood samples obtained from children after anti-malarial treat-
ment for a clinical malaria episode; samples from Cameroon were
collected prior to treatment from both symptomatically and
asymptomatically- infected individuals.2.1.1. Data from The Gambia
The study site, recruitment process, treatment regimes and
feeding experiments have been described previously (Targett
et al., 2001; Drakeley et al., 2004b; Sutherland et al., 2005). Brieﬂy,
malaria is seasonal and most transmission occurs between August
and December. The transmission intensity at the time of the stud-
ies was of the order of 10–20 infective bites/person/year. Children
attending the health centre at Farafenni were recruited in the
transmission season. Eligible children were aged 0.5–15 years
with a history of fever and Plasmodium falciparum asexual
parasitaemia >500/lL of blood in the absence of other species of
Plasmodium. Exclusion criteria included anaemia (packed cell
volume (PCV) < 20%); signs of severe malaria; inability to take
drugs orally; reported treatment with any anti-malarial within
the past 2 weeks; and any evidence of chronic disease or other
acute infection. After obtaining consent from parents or guardians,
children were randomly assigned to different treatment regimens
(Table 1). Following treatment, patients were brought to the
Medical Research Council (MRC) laboratory in Farafenni for mem-
brane-feeding experiments on days 4 (n = 45), 7 (n = 126), 10
(n = 6) and 14 (n = 9) after treatment. The study protocols were
approved by both the Joint Gambia Government/MRC Ethics
Committee and the London School of Hygiene and Tropical
Medicine Ethics Committee.2.1.2. Data from Kenya
The study in Kenya was conducted in Mbita, western Kenya, on
the shores of Lake Victoria. Symptomatic children aged 6 months-
10 years with uncomplicated malaria and a P. falciparum mono-
infectionwith a density of at least 1000 parasites/lLwere recruited.
Exclusion criteria were similar to those described for the studies in
The Gambia; anaemia in this case was deﬁned as haemoglobin
concentration lower than 5 g/dL. Children were randomized to
receive either artemether–lumefantrine (AL) or dihydroartemisi-
nin–piperaquine. Seven days after enrolment, individuals aged
2–10 years with and without microscopically conﬁrmed gameto-
cytes were recruited for membrane-feeding experiments; however,
the current analyses were restricted to microscopically conﬁrmed
gametocyte carriers. The study protocol received ethical approval
from the Ethical Review Committee of the Kenya Medical Research
Institute and the Ethics Committee of the London School of Hygiene
andTropicalMedicine The trialwas registeredonline at <http://clin-
icaltrials.gov/ct2/show/NCT00868465>.
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Two separate studies were conducted in Cameroon in 1995–
1998 (Cameroon 1 (Bonnet et al., 2000; Gouagna et al., 2004))
and in 1995–1996 (Cameroon 2 (Mulder et al., 1999)). In the ﬁrst
study, gametocyte carriers (aged 4–38 years) were recruited
during community-wide cross-sectional surveys in the district of
Mengang, where annual malaria transmission intensity is around
100 infective bites/person/year (Bonnet et al., 2003). In the second
study, 55 gametocyte carriers (aged 1–63 years) were recruited
among patients of the Messa dispensary in an urban quarter of
Yaoundé and exposed to a transmission intensity of 34 infectious
bites per person per year (van der Kolk et al., 2003). Of these, 5.5%
(3/55) presented with a temperature P37.5 C (Mulder et al.,
1999). In both studies, individuals with gametocytes by micros-
copy were selected for membrane-feeding experiments. Individu-
als with asexual parasites received anti-malarial treatment
following national guidelines after sampling for membrane feeds
was completed. The projects were approved by the National Ethical
Clearance Committee for Cameroon.
2.2. Membrane feeding and mosquito dissection
Venous blood samples (2–4 ml) were obtained from children
whose parent or guardian had given speciﬁc consent for the proce-
dure. Venous blood in citrate–phosphate dextrose (The Gambia) or
heparin (Cameroon, Kenya) was centrifuged, and the plasma was
removed. After being washed, the red blood cell pellet was split
into two aliquots of 300–500 lL each. These were resuspended to
a PCV of 33% in, respectively, the original AP and in pooled AB
serum from European donors with no history of malaria exposure
(CS). Each suspension then was fed to 50–100 3–5 day old female
Anopheles gambiae sensu stricto mosquitoes. In studies from The
Gambia, the next generation progeny of wild-caught gravid female
mosquitoes were used; locally reared laboratory strain mosquitoes
that were adapted to feeding on a membrane feeder were used in
Cameroon (Tchuinkam et al., 1993) and Kenya (Bousema et al.,
2006c). In all studies, starved mosquitoes were allowed to feed
for 15–30 min via an artiﬁcial membrane attached to a water-jack-
eted glass feeder maintained at 37 C. After feeding, blood-fed
mosquitoes were kept at 26–28 C with permanent access to a
10% sucrose solution without further blood meals. Mosquito mid-
guts were dissected out 7–8 days later in PBS (The Gambia) or 2%
(Cameroon, The Gambia) or 0.5% mercurochrome (Kenya) in dist-
iled water; the number of oocysts – a developmental stage of the
parasite found on the insect midgut – was recorded.
2.3. Data analysis
Data were entered using Epi-Info or MS-Access and analysed
using Stata version 11 (Stata Corporation, Texas, USA). Analyses
were restricted to experiments on microscopically conﬁrmed
gametocyte carriers that had at least 10 mosquitoes dissected
and resulted in at least one infected mosquito in the CS and/or
AP experiment. The latter criterion was invoked to rule out techni-
cal problems with the DMFA. The relationship between gameto-
cyte density and mosquito infection rates was visualised for all
data combined by grouping mosquito feeding experiments accord-
ing to the density of gametocytes in the blood ingested (into 20
evenly spaced groups on the log-scale). A Bland–Altman (differ-
ence) plot was created to visualise the difference between the
proportion of mosquitoes that was infected after feeding on a
blood sample with CS or AP. Oocyst counts were highly over-
dispersed (mean = 2.19; S.D. = 11.51) and were presented in cate-
gories: 0, 1–2, 3–5, 6–15, 16–50 and >50 oocysts.
The studies in The Gambia recruited individuals from a wide
age range (0.5–15 years) who were treated with artemisinin-combination therapy (ACT) and non-ACT treatment, recruited at
the start and through the transmission season and of whom a pro-
portion presented with gametocytes at enrolment, i.e. 4–14 days
before membrane feeding. We therefore used the combined data-
sets from The Gambia to determine factors associated with TRA.
The inﬂuence of host factors was examined in two ways. Firstly,
the prevalence of infectiousness among donors, deﬁned as the pro-
portion of individuals that provided a gametocyte-positive blood
sample which resulted in at least one infected mosquito, was
compared between CS and AP feeds for: different age-groups (<5
compared with P5 years); season of enrolment (peak compared
with start of transmission season); treatment (non-ACT compared
with ACT); history of microscopic gametocytaemia (gametocyte-
free versus gametocytes present at enrolment); gametocyte den-
sity at the day of membrane feeding above or below the median
value (50 gametocytes/lL). Different feeding days were combined.
The McNemar test was used to test for a difference between paired
CS and AP experiments. Subsequently, the proportion of infected
mosquitoes was compared between CS and AP feeds for the same
categories of participants. A multilevel logistic regression model
was used for this purpose using a multilevel generalised linear
model (GLLAMM, Stata version 11; Stata Corporation, Texas,
USA). This model incorporated clustering per patient and random
effects to account for differences between studies. Because mos-
quito infection rates were strongly associated with gametocyte
density, all analyses except those directly testing the inﬂuence of
having a high gametocyte density (P50 gametocytes/lL) at the
time of membrane feeding were adjusted for log (ln) transformed
gametocyte density. The GLLAMM model was also used for multi-
variate analyses where experiments with CS were used as refer-
ence category. Interaction terms were included in the model;
variables were selected for the multivariate model if P < 0.05 in
the univariate analyses and retained in the model if P < 0.10.3. Results
3.1. The association between gametocyte density and mosquito
infection rates
There was a positive association between gametocyte density
and the proportion of infected mosquitoes in CS and AP experi-
ments when all studies were combined (Fig. 1). Mosquito infection
rates were consistently higher in CS experiments compared with
AP experiments (Figs. 1 and 2). The difference between mosquito
infection rates in paired CS-AP experiments was plotted against
the average proportion of infected mosquitoes (Fig. 2). This
Bland–Altman plot indicated that in 68.2% of the paired experi-
ments the proportion of infected mosquitoes in the CS experiment
was higher than that in the AP experiment (P = 0.006).
The proportion of infected mosquitoes was statistically signiﬁ-
cantly higher in CS experiments compared with AP experiments
for The Gambia (Fig. 3, P < 0.001), Cameroon 1 (P = 0.03) and
Cameroon 2 (P = 0.004), after adjustment for the correlation be-
tween observations from the same individual and study-year (only
applicable for The Gambia). The increased proportion of infected
mosquitoes in the CS experiments compared with the AP experi-
ments was not statistically signiﬁcant for the trial in Kenya
(P = 0.29). Among infected mosquitoes, there was little evidence
for a difference in oocyst burden between CS and AP feeds. There
was no difference in intensity of infection (oocyst counts among
infected mosquitoes) between CS and AP feeds in the combined
Gambia data (P = 0.92), the Kenya data (P = 0.11) and the ﬁrst trial
in Cameroon (P = 0.12), after adjusting for correlation between
observations from the same individual and, where applicable,
study-year. Oocyst counts in infected mosquitoes were higher in
Fig. 1. The relationship between gametocyte density by microscopy and the
proportion of infected mosquitoes. Light grey circles indicate the proportion of
infected mosquitoes after feeding on blood samples with control serum (CS); dark
grey circles indicate autologous plasma (AP). The sizes of the circles are propor-
tional to the number of mosquitoes dissected for a given range of gametocyte
densities. The dataset combines observations from studies in The Gambia (1998–
2002; n = 106), Kenya (2009; n = 11) and Cameroon (1995–1998; n = 74).
Fig. 2. Bland–Altman (difference) plot comparing paired experiments with control
serum (CS) and autologous plasma (AP). Each dot represents a paired CS-AP
experiment. The mean proportion of infected mosquitoes is given on the X-axis and
the difference between AP and CS experiments on the Y-axis. A positive value
indicates a higher mosquito infection rate for CS feeds. In 68.2% (150/220) of the
paired experiments the mosquito infection rate was higher in the CS experiment
compared with the AP experiment (positive values); in 29.5% (65/220) of the
experiments the infection rate was higher in the AP experiment (negative values);
in 2.3% (5/220) of the experiments the proportion of infected mosquitoes was
identical for CS and AP feeds.
Fig. 3. Oocyst burdens in mosquitoes after feeding on blood samples with control
serum (CS) or autologous plasma (AP) in different experiments. Bars indicate the
proportion of mosquitoes with the indicated oocyst burden after feeding on blood
samples with control serum (CS) or autologous plasma (AP) in studies in The
Gambia (1998–2002), Kenya (2009), Cameroon 1 (1997) and Cameroon 2 (1995).
The asterisk indicates a statistically signiﬁcant difference between CS and AP
experiments in the proportion of mosquitoes with P1 oocyst.
296 T. Bousema et al. / International Journal for Parasitology 41 (2011) 293–300CS compared with AP feeds in the second trial in Cameroon
(P = 0.01).
3.2. Factors associated with TRA
The dataset from the combined Gambian trials was the largest
dataset and provided most details of human host factors. Because
these trials showed no evidence for differing oocyst counts amonginfected mosquitoes between CS and AP feeds, the analyses were
done on the prevalence of infectiousness (i.e. the proportion of
samples infecting at least one mosquito) and the proportion of in-
fected mosquitoes. The proportion of individual donor samples
that infected at least one mosquito was higher after serum replace-
ment, although at borderline signiﬁcance (P = 0.05, Table 2). This
difference was more pronounced when the proportion of infected
mosquitoes was considered (P < 0.001). A higher infectivity in CS
compared with AP feeds was found for samples from children older
than 5 years of age, samples from individuals who presented with
gametocytes at enrolment and samples from individuals who were
sampled at the end of the transmission season. The proportion of
infected mosquitoes increased after serum replacement for indi-
viduals with low and high gametocyte densities but the effect of
serum on transmissibility was more pronounced in those with
higher gametocyte densities. The type of treatment (ACT versus
non-ACT) did not inﬂuence the transmission-reducing capacity of
serum.
To determine independent predictors of TRA, a multivariate
model was built with CS experiments as the reference group
(Table 3). This model adjusted estimates for gametocyte density
at the time of feeding and correlations between observations from
the same individual, and incorporated a random effect for study-
year. Factors associated with TRA in the univariate analysis were
identical to those in Table 2: gametocytes present at the preceding
enrolment visit, older age and sampling late in the season. In the
multivariate model, however, only the presence of gametocytes
at enrolment and sampling late in the season were signiﬁcantly
associated with lower mosquito infection rates after adjustment
for gametocyte density, correlations between observations from
the same individual and study year.4. Discussion
In this study, we describe the prevalence of transmission reduc-
ing immune responses in naturally infected individuals from three
malaria endemic countries. All studies showed evidence for TRA
that was associated with several indicators of increased recent
exposure to gametocytes.
When combining successful membrane-feeding experiments of
201 naturally infected individuals, we observed a clear association
Table 2
Factors associated with transmission reducing activity (TRA) in The Gambian dataset.
Variable Prevalence of infectiousness P-valuea Proportion infected mosquitoes OR, P-valueb
All data AP: 63.8 (74/116)
CS: 77.6 (90/116)
p = 0.05 AP: 11.6 (278/2391)
CS: 17.2 (433/2518)
0.60 (0.50–0.72)
P < 0.001
Gametocyte density at feeding
<50 gametocytes/lL AP: 62.2 (31/50)
CS: 70.0 (35/50
p = 0.49 AP: 7.2 (76/1049)
CS: 10.2 (112/1101
0.72 (0.52–0.99)
P = 0.045
P50 gametocytes/lL AP: 65.2 (43/66)
CS: 83.3 (66/66)
p = 0.04 AP: 15.0 (201/1341)
CS: 22.7 (321/1417)
0.54 (0.43–0.68)
P < 0.001
Gametocyte prevalence at presentation
Yes AP: 56.1 (23/41)
CS: 87.8 (36/41)
p = 0.007 AP: 10.8 (88/818)
CS: 22.4 (183/817)
0.36 (0.26–0.49)
P < 0.001
No AP: 64.7 (44/68)
CS: 75.0 (51/68)
p = 0.27 AP: 11.6 (168/1449)
CS: 13.2 (203/1541)
0.87 (0.68–1.11)
P = 0.26
Age
Under 5 years AP: 65.4 (34/52)
CS: 67.3 (35/52)
p = 0.87 AP: 9.5 (101/1061)
CS: 10.5 (116/1101)
0.84 (0.62–1.14)
P = 0.27
Over 5 years AP: 60.0 (33/55)
CS: 89.1 (49/55)
p = 0.003 AP: 12.5 (140/1123)
CS: 19.5 (232/1193)
0.55 (0.43–0.71)
P < 0.001
Drug
Non-ACT AP: 63.6 (49/77)
CS: 77.9 (60/77)
p = 0.10 AP: 11.3 (180/1595)
CS: 16.7 (270/1616)
0.59 (0.47–0.74)
P < 0.001
ACT AP: 64.1 (25/39)
CS: 76.9 (30/39)
p = 0.30 AP: 12.3 (98/796)
CS: 18.1 (163/902)
0.62 (0.45–0.86)
P = 0.004
Season
Early AP: 69.6 (32/46)
CS: 73.9 (34/46)
p = 0.69 AP: 11.7 (101/865)
CS: 11.8 (105/888)
0.99 (0.72–1.38)
P = 0.97
Late AP: 57.1 (40/70)
CS: 82.9 (58/70)
p<0.001 AP: 11.6 (177/1526)
CS: 20.1 (328/1630)
0.47 (0.37–0.59)
P < 0.001
a By McNemar test for paired control serum-autologous plasma (CS–AP) observations.
b By Generalised Linear Latent and Mixed Models (GLAMM), adjusting for gametocyte density at the time of feeding (except for the variable ‘gametocyte density’) and
correlations between observations from the same individual and study-year. OR, odds ratio.
Table 3
Independent predictors of mosquito infection prevalence in the Gambian dataset.
Results of Generalised Linear Latent and Mixed Models (GLAMM) on the proportion of
infected mosquitoes. Estimates were adjusted for gametocyte density, the correlation
between observations from the same individuals and a random effect was added for
study year. Variables were added to the model if P < 0.05 in the univariate model
(adjusting for gametocyte density) and retained in the model if P < 0.05 in the
multivariate model through backward elimination of non-signiﬁcant variables.
Univariate
OR (95% CI)
P-value Multivariate
OR (95% CI)
P-value
Control serum 1.0 (ref) 1.0 (ref)
Autologous plasma
Gametocytes at
enrolment
0.36 (0.26–0.49) <0.001 0.52 (0.37–0.74) <0.001
Over 5 years
of age
0.58 (0.45–0.75) <0.001 –
Late in the season 0.49 (0.39–0.61) <0.001 0.62 (0.48–0.80) <0.001
Gametocyte
density (ln)/lL
1.34 (1.17–1.53) <0.001 1.40 (1.20–1.62) <0.001
OR, odds ratio; CI, conﬁdence interval; ref, reference category.
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Although this association was evident for both experiments with
permissive CS from non-exposed donors and experiments using
AP, mosquito infection rates were consistently higher in CS exper-
iments. Replacing AP by CS resulted in signiﬁcantly higher infec-
tion rates in two-thirds of all membrane-feeding experiments.
The higher infectivity in CS feeds was well captured by the preva-
lence scale (i.e. the presence or absence of oocysts) and there was
little to be gained by analysis of oocyst densities in infected mos-
quitoes in most of the datasets. In univariate analyses, higher
gametocyte densities at the time of membrane feeding, gameto-
cyte carriage during the week prior to the day of membrane feed-
ing, older age of children and sampling later in the transmissionseason were all associated with TRA, deﬁned as either a higher
likelihood of transmission-success in paired CS-AP experiments
or a higher proportion of infected mosquitoes in CS experiments.
A multivariate model indicated that the presence of gametocytes
during the week prior to the experiment and sampling late in the
transmission season were independently associated with increased
TRA. Increased TRA in children that carried gametocytes during the
week prior to the feeding experiment suggests that recent expo-
sure to gametocytes is associated with TRA. A rapid acquisition
of antibody responses to Pfs48/45 and Pfs230, both associated with
naturally acquired TRA (Bousema et al., 2006a), was previously
shown in individuals newly exposed to malaria (Ong et al., 1990;
Bousema et al., 2006b). It is therefore plausible that transmis-
sion-reducing antibodies were acquired or boosted in response to
recent exposure to gametocyte antigens. Some exposure to game-
tocyte antigens will have remained undetected by relying on
microscopy that may underestimate gametocyte carriage consider-
ably (Ali et al., 2006; Bousema et al., 2006c; Schneider et al., 2006;
Shekalaghe et al., 2007; Mens et al., 2008). It is plausible that some
of the individuals who developed gametocytes after treatment had
sub-patent gametocytes at enrolment (Ali et al., 2006; Schneider
et al., 2006). These individuals, however, were less likely to show
transmission reducing immune responses at the time of feeding
than those who had microscopically detectable gametocytes at
enrolment. This suggests that exposure to relatively high density
(i.e. microscopically detectable) gametocytes several days before
the experiment is needed to elicit functional TRA. This observation
is in line with the hypothesis that transmission reducing immunity
is rapidly induced and depends on recent exposure to gametocytes
(Bousema et al., 2006a). A similar biological mechanism could be
responsible for the observed increase in TRA towards the end of
the transmission season. Exposure to gametocytes shows consider-
able seasonal ﬂuctuation with a higher prevalence and density of
298 T. Bousema et al. / International Journal for Parasitology 41 (2011) 293–300gametocyte carriage in the transmission season compared with the
dry season (Drakeley et al., 2006a; Ouedraogo et al., 2008). The
proportion of children who have been exposed to gametocytes in
the weeks before the membrane-feeding experiments will there-
fore be highest towards the end of the transmission season, result-
ing in higher levels of TRA. These ﬁndings also indirectly support
the short-lived nature of transmission reducing immune re-
sponses. If cumulative life-long exposure to gametocytes was key
to the acquisition and maintenance of transmission reducing im-
mune responses, as observed for pre-erythrocytic and blood-stage
immune responses (Del Giudice et al., 1990; Wipasa et al., 2002),
one would expect age to be the dominant factor predicting TRA.
An effect of age on infectiousness that is independent of gameto-
cyte density was found in some (Githeko et al., 1992; Toure
et al., 1998; Schneider et al., 2007) but not all (Graves et al.,
1988a; Tchuinkam et al., 1993; Drakeley et al., 2000) studies. Our
experiments from The Gambia only included children with a med-
ian age of 4 years (range 0.5–15 years) and we therefore cannot
extrapolate our ﬁndings to adults, who appear to have a markedly
lower exposure to gametocytes than children (Drakeley et al.,
2006a). In multivariate models, age lost its inﬂuence on TRA after
adjustment for recent exposure to gametocytes. This suggests the
association between age and transmission reducing immune re-
sponses is complex. Age could be an indicator of better developed
clinical immune responses that change malaria disease progression
and treatment seeking behaviour. We hypothesise that in our pop-
ulation of children, older age allowed infections to remain asymp-
tomatic for a longer period, thereby postponing treatment seeking
(von Seidlein et al., 2002; Mota et al., 2009) and allowing for a
longer period of potential gametocyte production. This would
again indicate an inﬂuence of higher recent exposure to gameto-
cytes in older children.
When considering our individually paired AP–CS experiments,
we found evidence for an increased transmission in AP compared
with CS experiments in 3.4% of the experiments (4/116; data not
shown). The phenomenon of transmission enhancement has been
reported in other ﬁeld studies (Graves et al., 1988b; Premawansa
et al., 1994) and may be a real biological phenomenon rather than
an artefact resulting from variation in membrane feeding assays
(van der Kolk et al., 2006). The biological mechanism is unclear.
In some studies (Peiris et al., 1988; Gamage-Mendis et al., 1992;
Healer et al., 1999) transmission enhancement was linked to the
presence of very low concentrations of anti-gamete antibodies
but this was not conﬁrmed in the largest study on transmission
enhancement in P. falciparum (van der Kolk et al., 2006). The
importance of this phenomenon at a population level will require
further study and our limited number of samples showing
enhancement did not allow us to determine associated factors.
Our ﬁndings illustrate some of the difﬁculties encounteredwhen
doing transmission experiments under ﬁeld conditions. Mosquito
infection rates differed between study sites (Stepniewska et al.,
2008) and the association between gametocyte densities and mos-
quito infection rates can be highly variable (Graves, 1980; Carter
and Graves, 1988; Sinden et al., 1996; Boudin et al., 2004; Coleman
et al., 2004; Schneider et al., 2007; Ouedraogo et al., 2009). Even
when cultured gametocytes are used under highly standardised lab-
oratory conditions, the proportion of infected mosquitoes and the
number of oocysts resulting from a given gametocyte density can
vary considerably (van der Kolk et al., 2004). This variation is largest
at low gametocyte concentrations (van der Kolk et al., 2004) and is
partly a consequence of the narrow age range over which gameto-
cytes are infectious (Lensen et al., 1999; Hallett et al., 2006). The
type of anticoagulant used may affect oocyst development
(Ponnudurai et al., 1989; Solarte et al., 2007), an effect that has been
best described for EDTA,whichmay reduce oocyst numbers (Solarte
et al., 2007). Such an effect will not have inﬂuenced our conclusionssince our analyses were based on pair-wise comparisons of samples
from the same individual (i.e. with the same anticoagulant) or
restricted to data from the Gambia where only citrate phosphate
dextrose was used. Similar to variation in the highly standardised
SMFA, we expect there will be considerable variation in TRA mea-
sured by DMFA (Mulder et al., 1999; van der Kolk et al., 2004). This
makes it complicated to draw ﬁrm conclusions from individual
cross-sectional observations on TRA. Longitudinal studies are there-
fore needed to test the causality of our ﬁndings. In future longitudi-
nal studies the acquisition rate and longevity of TRA should be
determined in repeated membrane feeding assays on naturally
infected individuals.
The current ﬁndings conﬁrm the presence of TRA in naturally-
exposed populations and provide biologically plausible support
for the hypothesis that TRA depends on recent exposure to game-
tocytes. It is well established that transmission can be reduced by
antibodies to the gametocyte/gamete antigens Pfs 48/45, Pfs 230
and PfHAP2 (Sauerwein, 2007; Targett and Greenwood, 2008)
and the ELISA titer of antibodies against these antigens is related
to the level of TRA (Roeffen et al., 1996; Drakeley et al., 2004a;
Bousema et al., in press). Further dissection of the speciﬁc contri-
bution to TRA of these antibodies, and of other immune responses,
is required. The data presented here strongly suggest that recent
gametocyte exposure is a requirement for effective TRA. Thus
vaccines designed to block transmission by mimicking natural
TRA will have to overcome this requirement for boosting by
antigen exposure, if they are to be effective tools for reducing or
interrupting transmission of P. falciparum.Acknowledgements
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